The NDA submission in Q1 2027 is the next key catalyst. Monitor FDA acceptance and priority review status, which could drive further upside. The durability of response and manageable safety profile support the accelerated approval pathway.
Drug in focus
PMVP drug pipeline →rezatapopt
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2 (pivotal)
- Time to market
- NDA submission planned for Q1 2027 under accelerated approval pathway. If accepted and approved under standard review timelines, potential FDA decision could come in late 2027 or early 2028.
- Next catalyst
- NDA filing · Q1 2027
What to watchThe next catalyst is the late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 on November 20, 2026, roughly 9 days away. Positive data could reinforce the NDA submission narrative and support the stock, while disappointing results (weaker efficacy or safety signals) could undermine the accelerated approval path. The NDA submission itself, planned for Q1 2027, is the next major binary event after ENA.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PMV Pharma reported positive Phase 2 data for rezatapopt in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer, with a 48% ORR and 10.4-month median duration of response in the primary analysis population. The company plans to submit an NDA for accelerated approval in Q1 2027.
Key Facts
- 48% confirmed ORR in primary analysis of 65 platinum-resistant/refractory ovarian cancer patients
- 10.4-month median duration of response in primary analysis population
- 36% ORR across all 168 evaluable patients in overall population
- NDA submission for accelerated approval planned in Q1 2027
- FDA Fast Track and Orphan Drug Designation already granted
- Safety profile manageable; 6% discontinuation rate due to TRAEs
Financial Impact
PMV Pharma market cap is $92M; positive Phase 2 data and planned NDA submission represent a potential transformative event for this early-stage biotech with no approved products.
Risk Factors
- NDA submission and approval are not guaranteed; FDA may require additional trials
- Competition from other TP53-targeting therapies and standard-of-care options
- Company has no approved products and relies on successful regulatory and commercial execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3407616 |
Track record
14 reports on PMVP
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +29.46% at T+20 after the Aug 31, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 20, 20261d ago Press Release Bullish 7/10 Viewing Entry $1.20 Now $0.8760 −27.00% settles Dec 21
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.22 Now $0.8760 −28.20% settles Dec 16
- Nov 10, 202611d ago 8-K Neutral 5/10 Entry $1.22 Now $0.8760 −28.20% settles Dec 9
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $1.78 to $1.31 Now $0.8760 −50.79% ▼ −26.40% −23.94% vs SPY
- Aug 31, 202611w ago Press Release Bearish 8/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
- Aug 31, 202611w ago 8-K Bullish 7/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
- Aug 31, 202611w ago Press Release Bearish 6/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
- Aug 31, 202611w ago Press Release Bullish 8/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
- Aug 14, 202614w ago 8-K Neutral 5/10 No price data
- Aug 14, 202614w ago Press Release Bullish 6/10 Entry $1.26 to $1.46 Now $0.8760 −30.48% ▲ +15.87% +17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers